Multicenter Analysis of Glucocerebrosidase Mutations in Parkinson's Disease
Open accessThe DOI matches its Crossref record; 42 of the 43 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Recent studies indicate an increased frequency of mutations in the gene encoding glucocerebrosidase (GBA), a deficiency of which causes Gaucher's disease, among patients with Parkinson's disease. We aimed to ascertain the frequency of GBA mutations in an ethnically diverse group of patients with Parkinson's disease. METHODS: Sixteen centers participated in our international, collaborative study: five from the Americas, six from Europe, two from Israel, and three from Asia. Each center genotyped a standard DNA panel to permit comparison of the genotyping results across centers. Genotypes and phenotypic data from a total of 5691 patients with Parkinson's disease (780 Ashkenazi Jews) and 4898 controls (387 Ashkenazi Jews) were analyzed, with multivariate logistic-regression models and the Mantel-Haenszel procedure used to estimate odds ratios across centers. RESULTS: All 16 centers could detect two GBA mutations, L444P and N370S. Among Ashkenazi Jewish subjects, either mutation was found in 15% of patients and 3% of controls, and among non-Ashkenazi Jewish subjects, either mutation was found in 3% of patients and less than 1% of controls. GBA was fully sequenced for 1883 non-Ashkenazi Jewish patients, and mutations were identified in 7%, showing that limited mutation screening can miss half the mutant alleles. The odds ratio for any GBA mutation in patients versus controls was 5.43 across centers. As compared with patients who did not carry a GBA mutation, those with a GBA mutation presented earlier with the disease, were more likely to have affected relatives, and were more likely to have atypical clinical manifestations. CONCLUSIONS: Data collected from 16 centers demonstrate that there is a strong association between GBA mutations and Parkinson's disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“A compartment located at the trans Golgi where autolysosomes and MTOR accumulate during RAS-induced senescence”
From Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). (2016) · cites this paper as [1769]
Experimental — accuracy not yet measuredIn the citing paper
“there is an increased frequency of mutations in the gene encoding GBA among patients with Parkinson’s disease (e.g. Aharon-Peretz et al. 2004; Clark et al. 2007; Gan-Or et al. 2008; Lwin et al. 2004), and vice versa (Sidransky et al. 2009).”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Metabolic and Molecular Bases of Inherited Disease
Scriver, R. C. (1995) · Medical Entomology and Zoology · Cited by 12,101
The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease.
Gibb, W. R., & Lees, A. J. (1988) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.51.6.745 · Cited by 3,481
ON ESTIMATING THE RELATION BETWEEN BLOOD GROUP AND DISEASE
WOOLF, B. (1955) · Annals of Human Genetics · doi:10.1111/j.1469-1809.1955.tb01348.x · Cited by 2,723
Glucocerebrosidase mutations in clinical and pathologically proven Parkinson’s disease
Neumann, J., Bras, J., Deas, E., O'Sullivan, S. S., Parkkinen, L., Lachmann, R. H., Li, A., Holton, J., Guerreiro, R., Paudel, R., et al. (2009) · Brain · doi:10.1093/brain/awp044 · Cited by 696 · cited 1×
“R496H (7 recombinant alleles) (10) c.84dupG ( 17 )”
Self-citationGaucher disease: mutation and polymorphism spectrum in the glucocerebrosidase gene (GBA)
Hruska, K. S., LaMarca, M. E., Scott, C. R., & Sidransky, E. (2008) · Human Mutation · doi:10.1002/humu.20676 · Cited by 678
Self-citationMutations in the Glucocerebrosidase Gene and Parkinson's Disease in Ashkenazi Jews
Aharon-Peretz, J., Rosenbaum, H., & Gershoni-Baruch, R. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033277 · Cited by 597
Self-citationOccurrence of Parkinson's syndrome in type 1 Gaucher disease
Neudorfer, O., Giladi, N., Elstein, D., Abrahamov, A., Turezkite, T., Aghai, E., Reches, A., Bembi, B., & Zimran, A. (1996) · QJM · doi:10.1093/qjmed/89.9.691 · Cited by 401
Self-citationGaucher disease: complexity in a “simple” disorder
Sidransky, E. (2004) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2004.08.015 · Cited by 399 · cited 7×
“Patients 311 (0) 186:123 (2) NP 7 (2) Controls 473 (0) 267:206 64.1 8 ( 2 )”
InfluentialSelf-citationGlucocerebrosidase mutations in subjects with parkinsonism
Lwin, A. (2004) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2003.11.004 · Cited by 371
Parkinsonism among Gaucher disease carriers
Goker-Alpan, O., Schiffmann, R., LaMarca, M. E., Nussbaum, R. L., McInerney-Leo, A., & Sidransky, E. (2004) · Journal of Medical Genetics · doi:10.1136/jmg.2004.024455 · Cited by 366
Self-citation
Research works printed but not linked: 1
- 10.1002/(sici)1096-8652(199907)61:3<216::aid-ajh12>3.0.co;2-b · doi:10.1002/(sici)1096-8652(199907)61:3<216::aid-ajh12>3.0.co;2-b
Cited by
Items 601–700 of 1,008
Strong association between glucocerebrosidase mutations and Parkinson's disease in Sweden
Ran, C., Brodin, L., Forsgren, L., Westerlund, M., Ramezani, M., Gellhaar, S., Xiang, F., Fardell, C., Nissbrandt, H., Söderkvist, P., et al. (2016) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2016.04.022 · Cited by 60
“Many other GBAmutations have been reported to influence the risk of developing PD, and the frequency of each variant differs globally according to genetic background (Gan-Or et al., 2015; Sidransky et al., 2009).”
BackgroundResultInfluentialSharma, J., di Ronza, A., Lotfi, P., & Sardiello, M. (2018) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-080317-061804 · Cited by 55
Velez-Pardo, C., Lorenzo-Betancor, O., Jimenez-Del-Rio, M., Moreno, S., Lopera, F., Cornejo-Olivas, M., Torres, L., Inca-Martinez, M., Mazzetti, P., Cosentino, C., et al. (2019) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2019.01.030 · Cited by 56
Self-citationParkinson's and Lewy body dementia CSF biomarkers
Parnetti, L., Paciotti, S., Farotti, L., Bellomo, G., Sepe, F. N., & Eusebi, P. (2019) · Clinica Chimica Acta · doi:10.1016/j.cca.2019.04.078 · Cited by 61
Avenali, M., Toffoli, M., Mullin, S., McNeill, A., Hughes, D. A., Mehta, A. B., Blandini, F., & Schapira, A. H. V. (2019) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2019-320394 · Cited by 62
The Quebec Parkinson Network: A Researcher-Patient Matching Platform and Multimodal Biorepository
Gan‐Or, Z., Rao, T., Léveillé, E., Degroot, C., Chouinard, S., Cicchetti, F., Dagher, A., Das, S., Désautels, A., Drouin‐Ouellet, J., et al. (2019) · Journal of Parkinson s Disease · doi:10.3233/jpd-191775 · Cited by 64
Self-citationLong-Term Outcomes of Genetic Parkinson’s Disease
Aasly, J. O. (2020) · Journal of Movement Disorders · doi:10.14802/jmd.19080 · Cited by 59
Self-citationParkinson’s Disease and Dementia: A Longitudinal Study (DEMPARK)
Balzer‐Geldsetzer, M., Costa, A. S., Kronenbürger, M., Schulz, J. B., Röske, S., Spottke, A. E., Wüllner, U., Klockgether, T., Storch, A., Schneider, C. B., et al. (2011) · Neuroepidemiology · doi:10.1159/000331490 · Cited by 63
Self-citationGlucocerebrosidase mutations in diffuse Lewy body disease
Nishioka, K., Ross, O. A., Vilariño‐Güell, C., Cobb, S. A., Kachergus, J. M., Mann, D. M. A., Snowden, J. S., Richardson, A. M. T., Neary, D., Robinson, C. A., et al. (2010) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2010.09.009 · Cited by 57
Self-citationPlasma sphingolipid changes with autopsy‐confirmed Lewy body or Alzheimer's pathology
Savica, R., Murray, M. E., Persson, X.-M. T., Kantarci, K., Parisi, J. E., Dickson, D. W., Petersen, R. C., Ferman, T. J., Boeve, B. F., & Mielke, M. M. (2016) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2016.02.005 · Cited by 59
Berge‐Seidl, V., Pihlstrøm, L., Maple‐Grødem, J., Forsgren, L., Linder, J., Larsen, J. P., Tysnes, O., & Toft, M. (2017) · Neuroscience Letters · doi:10.1016/j.neulet.2017.08.040 · Cited by 55
Targeted sequencing of Parkinson’s disease loci genes highlights SYT11, FGF20 and other associations
Rudakou, U., Yu, E., Krohn, L., Ruskey, J. A., Asayesh, F., Dauvilliers, Y., Spiegelman, D., Greenbaum, L., Fahn, S., Waters, C. H., et al. (2021) · Brain · doi:10.1093/brain/awaa401 · Cited by 52
Self-citationTRIP12 ubiquitination of glucocerebrosidase contributes to neurodegeneration in Parkinson’s disease
Seo, B. A., Kim, D., Hwang, H., Kim, M. S., Ma, S.-X., Kwon, S., Kweon, S. H., Wang, H., Yoo, J. M., Choi, S., et al. (2021) · Neuron · doi:10.1016/j.neuron.2021.09.031 · Cited by 57
GBA-associated PD: chances and obstacles for targeted treatment strategies
Höglinger, G. U., Schulte, C., Jost, W. H., Storch, A., Woitalla, D., Krüger, R., Falkenburger, B. H., & Brockmann, K. (2022) · Journal of Neural Transmission · doi:10.1007/s00702-022-02511-7 · Cited by 62
Self-citationVrijsen, S., Vrancx, C., Vecchio, M. D., Swinnen, J. V., Agostinis, P., Winderickx, J., Vangheluwe, P., & Annaert, W. G. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.900338 · Cited by 58
“Dysfunction of Glucocerebrosidase 1 (GCase), a resident of the lysosomal lumen responsible for degradation of glucosylceramide and glucosylsphingosine, forms a risk factor for PD development (Sidransky et al., 2009; Ryan et al., 2019; Avenali et al., 2020).”
BackgroundPeña‐Díaz, S., García‐Pardo, J., & Ventura, S. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15030839 · Cited by 60
Genetics and iron in the systems biology of Parkinson’s disease and some related disorders
Funke, C., Schneider, S. A., Berg, D., & Kell, D. B. (2013) · Neurochemistry International · doi:10.1016/j.neuint.2012.11.015 · Cited by 54
Self-citationThe enigma of the E326K mutation in acid β-glucocerebrosidase
Horowitz, M., Pasmanik‐Chor, M., Ron, I., & Kolodny, E. H. (2011) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2011.07.002 · Cited by 59
Glucocerebrosidase mutations in a S erbian P arkinson's disease population
Kumar, K. R., Ramı́rez, A., Göbel, A., Kresojević, N. D., Svetel, M. V., Lohmann, K., Sue, C. M., Rolfs, A., Mazzulli, J. R., Alcalay, R. N., et al. (2012) · European Journal of Neurology · doi:10.1111/j.1468-1331.2012.03817.x · Cited by 54
Self-citationChoi, J. M., Kim, W. C., Lyoo, C. H., Kang, S. Y., Lee, P. H., Baik, J. S., Koh, S., Ma, H., Sohn, Y. H., Lee, M. S., et al. (2012) · Neuroscience Letters · doi:10.1016/j.neulet.2012.02.035 · Cited by 61
Guerreiro, R., Bras, J., Hardy, J., & Singleton, A. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu203 · Cited by 55
Self-citationLa maladie de Gaucher : quand y penser ?
Nguyen, Y., Stirnemann, J., & Belmatoug, N. (2019) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2018.11.012 · Cited by 68
de Oliveira, L. M., Barbosa, E. R., Aquino, C., Munhoz, R. P., Fasano, A. A., & Cury, R. G. (2019) · Movement Disorders Clinical Practice · doi:10.1002/mdc3.12795 · Cited by 54
Self-citationRecent Developments in LRRK2-Targeted Therapy for Parkinson’s Disease
Zhao, Y., & Dzamko, N. L. (2019) · Drugs · doi:10.1007/s40265-019-01139-4 · Cited by 58
Self-citationHuh, Y. E., Park, H. J., Chiang, M. S. R., Tuncali, I., Liu, G., Locascio, J. J., Shirvan, J. C., Hutten, S. J., Rotunno, M. S., Viel, C., et al. (2021) · npj Parkinson s Disease · doi:10.1038/s41531-021-00241-3 · Cited by 56
Glucosylceramidases and malignancies in mammals
Astudillo, L. M., Therville, N., Colacios, C., Ségui, B., Andrieu‐Abadie, N., & Levade, T. (2015) · Biochimie · doi:10.1016/j.biochi.2015.11.009 · Cited by 55
Papagiannakis, N., Koros, C., Stamelou, M., Simitsi, A., Maniati, M., Antonelou, R. C., Papadimitriou, D. A., Dermentzaki, G., Moraitou, M., Michelakakis, H., et al. (2017) · Neuroscience Letters · doi:10.1016/j.neulet.2017.11.012 · Cited by 55
Lerche, S., Wurster, I., Röeben, B., Zimmermann, M., Riebenbauer, B., Deuschle, C., Hauser, A., Schulte, C., Berg, D., Maetzler, W., et al. (2019) · Movement Disorders · doi:10.1002/mds.27884 · Cited by 54
“namely, Parkinson’s disease (PD) and dementia with Lewy bodies (DLB).(1,2) Clinically, PD and DLB patients carrying a GBA1 mutation (PDGBA, DLBGBA) present with an earlier age of onset, suffer more frequently from”
BackgroundSelf-citationNew hopes for disease modification in Parkinson's Disease
Poewe, W. H., Seppi, K., Marini, K., & Mahlknecht, P. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2020.108085 · Cited by 55
Choudhury, S. P., Bano, S., Sen, S., Suchal, K., Kumar, S., Nikolajeff, F., Dey, S. K., & Sharma, V. (2022) · npj Parkinson's Disease · doi:10.1038/s41531-022-00324-9 · Cited by 52
Richter, F., Stanojlović, M., Käufer, C., Gericke, B., & Feja, M. (2023) · Neurotherapeutics · doi:10.1007/s13311-022-01338-0 · Cited by 53
Sphingolipid metabolism in brain insulin resistance and neurological diseases
Mei, M., Liu, M., Mei, Y., Zhao, J., & Li, Y. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1243132 · Cited by 54
SCARB2 variants and glucocerebrosidase activity in Parkinson’s disease
Alcalay, R. N., Levy, O. A., Wolf, P., Oliva, P., Zhang, X. K., Waters, C., Fahn, S., Kang, U. J., Liong, C., Ford, B., et al. (2016) · npj Parkinson s Disease · doi:10.1038/npjparkd.2016.4 · Cited by 56
Self-citationWorking Memory in Alzheimer’s Disease and Parkinson’s Disease
Zokaei, N., & Husain, M. (2019) · Current topics in behavioral neurosciences · doi:10.1007/7854_2019_103 · Cited by 57
Chillag-Talmor, O., Giladi, N., Linn, S., Gurevich, T., El‐Ad, B., SILVERMAN, B. G., Friedman, N. L., & Peretz, C. (2011) · Journal of Parkinson s Disease · doi:10.3233/jpd-2011-11024 · Cited by 52
Self-citationPradas, E., & Martínez‐Vicente, M. (2023) · Cells · doi:10.3390/cells12010191 · Cited by 56
α-Synuclein Pathology in Synucleinopathies: Mechanisms, Biomarkers, and Therapeutic Challenges
Arias-Carrión, Ó., Guerra‐Crespo, M., Padilla-Godínez, F. J., Soto-Rojas, L. O., & Manjarrez, E. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26115405 · Cited by 58
“The association between glucocerebrosidase dysfunction and aSyn pathology suggests that lysosomal impairments and autophagy defects play pivotal roles in synucleinopathies [209,210].”
Yang, S., Gegg, M. E., Chau, D., & Schapira, A. H. V. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.104620 · Cited by 56
“Glucocerebrosidase gene (GBA1) mutations are recognised as the most important genetic risk factor for Parkinson's disease (PD) (Balestrino and Schapira, 2018; Sidransky et al., 2009).”
Granek, Z., Barczuk, J., Siwecka, N., Rozpędek‐Kamińska, W., Kucharska, E., & Majsterek, I. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032044 · Cited by 51
“The treatment of DLB includes cholinesterase inhibitors for cognitive and behavioral impairment symptoms of DLB: rivastigmine, galantamine and donepezil, memantine, atypical antipsychotic drugs for agitation, levodopa/carbidopa for parkinsonism, pimavanserin for psychosis, melatonin or clonazepam for RBD and personali…”
BackgroundInfluentialSphingolipids in neurodegenerative diseases
Pan, X., Dutta, D., Lu, S., & Bellen, H. J. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1137893 · Cited by 54
“Further, the presence of a single variant of GBA increases the PD risk by a factor of 5 (Sidransky et al., 2009).”
BackgroundBogetofte, H., Ryan, B. J., Jensen, P., Schmidt, S. I., Vergoossen, D. L. E., Barnkob, M. B., Kiani, L. N., Chughtai, U., Heon-Roberts, R., Caiazza, M. C., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112180 · Cited by 47
“2,18,35 We differentiated GBA-N370S patient and control iPSC lines using a well-established protocol 55 to generate high numbers of midbrain-specific dopamine neurons.”
GBA1 Variants and Parkinson’s Disease: Paving the Way for Targeted Therapy
Huh, Y. E., Usnich, T., Scherzer, C. R., Klein, C., & Chung, S. J. (2023) · Journal of Movement Disorders · doi:10.14802/jmd.23023 · Cited by 59
Parkinson’s Disease Genetic Loci in Rapid Eye Movement Sleep Behavior Disorder
Gan‐Or, Z., Girard, S., Noreau, A., Leblond, C. S., Gagnon, J., Arnulf, I., Mirarchi, C., Dauvilliers, Y. A., Désautels, A., Mitterling, T., et al. (2015) · Journal of Molecular Neuroscience · doi:10.1007/s12031-015-0569-7 · Cited by 50
Self-citationThe Genetics of Dementia With Lewy Bodies
Meeus, B., Theuns, J., & Broeckhoven, C. V. (2012) · Archives of Neurology · doi:10.1001/archneurol.2011.3678 · Cited by 50
“Contursi kindred4 60 (8) 5 (14) Most (?) 60 (46 [20-85]) 2 0 SN, NC AD (SNCA A53T) Iowa kindred5 22(?) 6 (12) 14 (49 [33-57]) 22 (34 [20-48]) 6 0 SN, NC AD (SNCA triplication) Family G6 10 (10) 3 (4) 6 (74 [70-78]) 7 (57 [48-74]) 1 0 SN, NC AD (Chr2p13) Family A7 4 (4) 3 (4) 4 (55 [35-73]) 4 (50 [28-71]) 2 0 SN, NC AD…”
Zheng, J., Chen, L., Skinner, O. S., Ysselstein, D., Remis, J. P., Lansbury, P. T., Skerlj, R. T., Mrosek, M., Heunisch, U., Krapp, S., et al. (2018) · Journal of the American Chemical Society · doi:10.1021/jacs.7b13003 · Cited by 52
Tamtaji, O. R., Hadinezhad, T., Fallah, M., Shahmirzadi, A. R., Taghizadeh, M., Behnam, M., & Asemi, Z. (2020) · Current Drug Targets · doi:10.2174/1389450120666191112155654 · Cited by 50
Sanyal, A., Novis, H. S., Gasser, E., Lin, S. C., & LaVoie, M. J. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00442 · Cited by 53
NLRP7 and the Genetics of Hydatidiform Moles: Recent Advances and New Challenges
Slim, R., & Wallace, E. P. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00242 · Cited by 53
“The same principle applies to other genes: ATP13A2 responsible for a juvenile onset of PD (93), GBA responsible for Gaucher’s disease (94, 95), ABCA1 responsible for Tangier disease (96), and MEFV responsible for familial Mediterranean fever (FMF) (97).”
BackgroundPará, C., Bose, P., & Pshezhetsky, A. V. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9030616 · Cited by 49
Predictors of RBD progression and conversion to synucleinopathies
de Natale, E. R., Wilson, H., & Politis, M. (2022) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-022-01171-0 · Cited by 52
Glial control of sphingolipid levels sculpts diurnal remodeling in a circadian circuit
Vaughen, J. P., Theisen, E. K., Rivas‐Serna, I. M., Berger, A. B., Kalakuntla, P. R., Anreiter, I., Mazurak, V. C., Rodriguez, T. P., Mast, J. D., Hartl, T. A., et al. (2022) · Neuron · doi:10.1016/j.neuron.2022.07.016 · Cited by 54
Yap, T. L., Jiang, Z., Heinrich, F., Gruschus, J. M., Pfefferkorn, C. M., Barros, M., Curtis, J. E., Sidransky, E., & Lee, J. C. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.610584 · Cited by 52
Self-citationSoria, F. N., Engeln, M., Martínez‐Vicente, M., Glangetas, C., López‐González, M. J., Doveró, S., Dehay, B., Normand, E., Vila, M., Favereaux, A., et al. (2017) · Human Molecular Genetics · doi:10.1093/hmg/ddx120 · Cited by 50
“Although homozygous mutations in GBA1 are linked to GD, heterozygous mutations of this gene are found in 5–10% of Parkinson’s disease (PD) and dementia with Lewy body (DLB) patients (1,2), making GBA1 mutations the most common genetic risk factor for these disorders (3,4).”
BackgroundAn update on the genetics of dementia with Lewy bodies
Vergouw, L. J. M., van Steenoven, I., van de Berg, W. D. J., Teunissen, C. E., Swieten, J. C. V., Bonifati, V., Lemstra, A. W., & de Jong, F. J. (2017) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2017.07.009 · Cited by 50
An unexpected player in Gaucher disease: The multiple roles of complement in disease development
Pandey, M. K., Grabowski, G. A., & Köhl, J. (2018) · Seminars in Immunology · doi:10.1016/j.smim.2018.02.006 · Cited by 52
β-Glucocerebrosidase activity in GBA -linked Parkinson disease: The type of mutation matters
Huh, Y. E., Chiang, M. S. R., Locascio, J. J., Liao, Z., Liu, G., Choudhury, K., Kuras, Y. I., Tuncali, I., Videnović, A., Hunt, A. L., et al. (2020) · Neurology · doi:10.1212/wnl.0000000000009989 · Cited by 57
“The disease risk and the rate of cognitive decline may be moderately elevated in this group in some studies.(2,5,21) (3) The heterozygous carriers of PD-associated GBA risk variants (risk variant GBA-PD) group includes patients with PD with PD-associated, protein-coding GBA variants (E326K, T369M, and E388K).”
BackgroundMuñoz, S. S., Petersen, D., Marlet, F. R., Kücükköse, E., & Galvagnion, C. (2020) · Biophysical Chemistry · doi:10.1016/j.bpc.2020.106534 · Cited by 53
Aging, cellular senescence and Parkinson's disease
Ma, Y., Erb, M. L., & Moore, D. J. (2025) · Journal of Parkinson s Disease · doi:10.1177/1877718x251316552 · Cited by 59
Current therapeutic strategies in Parkinson’s disease: Future perspectives
Kim, T. Y., & Lee, B. D. (2025) · Molecules and Cells · doi:10.1016/j.mocell.2025.100274 · Cited by 59
“…factors, including mutations in the leucine-rich repeat kinse 2 ( LRRK2) and glucosylcer-amidase ( GBA1) genes, have been linked to both familial and sporadic PD, underscoring the complexity of the underlying disease mechanisms (Di Maio et al., 2018; Eblan et al., 2005; Sidransky et al., 2009).”
Neuronal Forms of Gaucher Disease
Vitner, E. B., & Futerman, A. H. (2013) · Handbook of experimental pharmacology · doi:10.1007/978-3-7091-1511-4_20 · Cited by 52
Valle, M. C. D., Sleat, D. E., Zheng, H., Moore, D. F., Jadot, M., & Lobel, P. (2011) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m110.006403 · Cited by 50
Pchelina, S., Baydakova, G., Nikolaev, M. A., Senkevich, K. A., Emelyanov, A., Kopytova, A. E., Miliukhina, I. V., Yakimovskii, А. F., Timofeeva, A., Беркович, О. А., et al. (2018) · Movement Disorders · doi:10.1002/mds.27393 · Cited by 49
Lysosomal Ceramide Metabolism Disorders: Implications in Parkinson’s Disease
Paciotti, S., Albi, E., Parnetti, L., & Beccari, T. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9020594 · Cited by 52
“Although GBA mutation carriers have 5–6 fold increased risk to develop PD [14], the penetrance of PD in these people is low (from 7.”
BackgroundInfluentialCirculating extracellular vesicles: friends and foes in neurodegeneration
Calvani, R., Picca, A., Guerra, F., Coelho-Júnior, H. J., Bucci, C., & Marzetti, E. (2021) · Neural Regeneration Research · doi:10.4103/1673-5374.320972 · Cited by 51
Plasma Glucosylsphingosine in GBA1 Mutation Carriers with and without Parkinson's Disease
Surface, M., Balwani, M., Waters, C., Haimovich, A., Gan‐Or, Z., Marder, K. S., Hsieh, T., Song, L., Padmanabhan, S., Hsieh, F., et al. (2021) · Movement Disorders · doi:10.1002/mds.28846 · Cited by 52
Self-citationGenetic Defects and Pro-inflammatory Cytokines in Parkinson's Disease
Magnusen, A. F., Hatton, S. L., Rani, R., & Pandey, M. K. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.636139 · Cited by 47
Protein clearance strategies for disease intervention
Hommen, F., Bilican, S., & Vílchez, D. (2021) · Journal of Neural Transmission · doi:10.1007/s00702-021-02431-y · Cited by 51
Alpha-Synuclein and Cognitive Decline in Parkinson Disease
Fan, T.-S., Liu, S. C.-H., & Wu, R. (2021) · Life · doi:10.3390/life11111239 · Cited by 61
Defining the Riddle in Order to Solve It: There Is More Than One “Parkinson's Disease”
Outeiro, T. F., Alcalay, R. N., Antonini, A., Attems, J., Bonifati, V., Cardoso, F., Chesselet, M., Hardy, J., Madeo, G., McKeith, I. G., et al. (2023) · Movement Disorders · doi:10.1002/mds.29419 · Cited by 54
Avenali, M., Zangaglia, R., Cuconato, G., Palmieri, I., Albanese, A., Artusi, C. A., Bozzali, M., Buonaura, G. C., Cavallieri, F., Cilia, R., et al. (2023) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2023-332387 · Cited by 62
Bayati, A., & McPherson, P. S. (2024) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2024.107742 · Cited by 50
Saposin C Protects Glucocerebrosidase against α-Synuclein Inhibition
Yap, T. L., Gruschus, J. M., Velayati, A., Sidransky, E., & Lee, J. C. (2013) · Biochemistry · doi:10.1021/bi401191v · Cited by 45
Self-citationMolecular pathways in sporadic PD
Valente, E. M., Arena, G., Torosantucci, L., & Gelmetti, V. (2011) · Parkinsonism & Related Disorders · doi:10.1016/s1353-8020(11)70023-2 · Cited by 52
Sleep disorders and Parkinson disease; lessons from genetics
Gan‐Or, Z., Alcalay, R. N., Rouleau, G. A., & Postuma, R. B. (2018) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2018.01.006 · Cited by 53
Self-citationEvolution and clustering of prodromal parkinsonian features in GBA1 carriers
Mullin, S., Beavan, M. S., Bestwick, J. P., McNeill, A., Proukakis, C., Cox, T. M., Hughes, D. A., Mehta, A. B., Zetterberg, H., & Schapira, A. H. V. (2019) · Movement Disorders · doi:10.1002/mds.27775 · Cited by 50
den Heijer, J. M., Kruithof, A. C., van Amerongen, G., de Kam, M. L., Thijssen, E., Grievink, H. W., Moerland, M., Walker, M., Been, K., Skerlj, R. T., et al. (2021) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14772 · Cited by 47
Implications of Sphingolipids on Aging and Age-Related Diseases
Li, S., & Kim, H.-E. (2022) · Frontiers in Aging · doi:10.3389/fragi.2021.797320 · Cited by 49
The role of SCARB2 as susceptibility factor in Parkinson's disease
Hopfner, F., Schulte, E. C., Mollenhauer, B., Bereznai, B., Knauf, F., Lichtner, P., Zimprich, A., Haubenberger, D., Pirker, W., Brücke, T., et al. (2013) · Movement Disorders · doi:10.1002/mds.25349 · Cited by 46
Sphingolipids in mitochondria—from function to disease
Jamil, M., & Cowart, L. A. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1302472 · Cited by 48
Moraitou, M., Hadjigeorgiou, G. M., Monopolis, I., Dardiotis, E., Bozi, M., Vassilatis, D. K., Vilageliu, L., Grinberg, D., Xiromerisiou, G., Stefanis, L., et al. (2011) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2011.06.015 · Cited by 60
Gaucher disease and comorbidities: B‐cell malignancy and parkinsonism
Cox, T. M., Rosenbloom, B. E., & Barker, R. A. (2015) · American Journal of Hematology · doi:10.1002/ajh.24057 · Cited by 50
Refolding of helical soluble α‐synuclein through transient interaction with lipid interfaces
Rovere, M., Sanderson, J. B., Fonseca‐Ornelas, L., Patel, D. S., & Bartels, T. (2018) · FEBS Letters · doi:10.1002/1873-3468.13047 · Cited by 47
Protein Quality Control Pathways at the Crossroad of Synucleinopathies
de Mattos, E. P., Wentink, A. S., Nussbaum-Krammer, C. I., Hansen, C., Bergink, S., Melki, R., & Kampinga, H. H. (2020) · Journal of Parkinson s Disease · doi:10.3233/jpd-191790 · Cited by 47
“While homozygous mutations in the GCase-encoding gene GBA1 cause Gaucher’s disease [149], heterozygous mutations are a well-established risk factor for developing PD [150].”
BackgroundFrom cell lines to pluripotent stem cells for modelling Parkinson's Disease
Ferrari, E. S., Cardinale, A., Picconi, B., & Gardoni, F. (2020) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2020.108741 · Cited by 47
Argueti-Ostrovsky, S., Alfahel, L., Kahn, J., & Israelson, A. (2021) · Cells · doi:10.3390/cells10092438 · Cited by 48
Unbiased screen reveals ubiquilin-1 and -2 highly associated with huntingtin inclusions
Rutherford, N. J., Lewis, J. M., Clippinger, A. K., Thomas, M. A., Adamson, J. L., Cruz, P. E., Cannon, A. D., Xu, G. M., Golde, T. E., Shaw, G., et al. (2013) · Brain Research · doi:10.1016/j.brainres.2013.06.006 · Cited by 51
“For example, recessive mutations in the GBA gene encoding the enzyme glucocerebrocidase can cause Gaucher's disease, but the same heterozygous mutations also can be a risk factor for PD and dementia with Lewy bodies (DLB) (Sidransky et al., 2009).”
BackgroundInfluentialThe curious case of phenocopies in families with genetic Parkinson's disease
Klein, C., Chuang, R., Marras, C., & Lang, A. E. (2011) · Movement Disorders · doi:10.1002/mds.23853 · Cited by 47
Self-citationVoltage-gated calcium channels and Parkinson's disease
Hurley, M. J., & Dexter, D. T. (2011) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.11.006 · Cited by 55
Wang, Q., Liu, J., Guo, Y., Dong, G., Zou, W., & Chen, Z. (2019) · Brazilian Journal of Medical and Biological Research · doi:10.1590/1414-431x20198443 · Cited by 45
Kedariti, M., Frattini, E., Baden, P., Cogo, S., Civiero, L., Ziviani, E., Zilio, G., Bertoli, F., Aureli, M., Kaganovich, A., et al. (2022) · npj Parkinson s Disease · doi:10.1038/s41531-022-00354-3 · Cited by 47
Genome-wide assessment of Parkinson's disease in a Southern Spanish population
Bandrés‐Ciga, S., Price, T. R., Barrero, F. J., Sevilla, F. E., Pelegrina, J., Arepalli, S., Hernandez, D. G., Gutiérrez, B., Cervilla, J. A., Rivera, M., et al. (2016) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2016.06.001 · Cited by 45
Self-citationvon Linstow, C. U., Gan‐Or, Z., & Brundin, P. (2020) · Translational Neurodegeneration · doi:10.1186/s40035-020-00218-x · Cited by 50
Self-citationMutations in the glucocerebrosidase gene confer a risk for Parkinson disease in North Africa
Lesage, S., Condroyer, C., Hecham, N., Anheim, M., Belarbi, S., Lohman, E., Viallet, F., Pollak, P., Abada-Bendib, M., Dürr, A., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e318207b01e · Cited by 50
Self-citationGBA Mutations Are Associated With Earlier Onset and Male Sex in Dementia With Lewy Bodies
Gámez‐Valero, A., Prada-Dacasa, P., dos Santos, C. M. P., Adame-Castillo, C., Campdelacreu, J., Reñé, R., Gascón‐Bayarri, J., Ispierto, L., Álvarez, R., Ariza, A., et al. (2016) · Movement Disorders · doi:10.1002/mds.26593 · Cited by 47
Targeting α‐synuclein: Therapeutic options
Dehay, B., Decressac, M., Bourdenx, M., Guadagnino, I., Fernagut, P., Tamburrino, A., Bassil, F., Meissner, W. G., & Bézard, E. (2016) · Movement Disorders · doi:10.1002/mds.26568 · Cited by 48
Glycosphingolipid metabolism and its role in ageing and Parkinson’s disease
Wallom, K., Fernández‐Suárez, M. E., Priestman, D. A., Vruchte, D. T., Huebecker, M., Hallett, P. J., Isacson, O., & Platt, F. M. (2021) · Glycoconjugate Journal · doi:10.1007/s10719-021-10023-x · Cited by 47
Colucci, F., Avenali, M., Micco, R. D., Poli, M. F., Cerri, S., Stanziano, M., Bacila, A., Cuconato, G., Franco, V., Franciotta, D. M., et al. (2023) · BMJ Neurology Open · doi:10.1136/bmjno-2023-000535 · Cited by 47
Wang, R., Sun, H., Cao, Y., Zhang, Z., Chen, Y., Wang, X., Liu, L., Wu, J., Xu, H., Wu, D., et al. (2024) · Science Signaling · doi:10.1126/scisignal.adk8249 · Cited by 53
Yaribash, S., Mohammadi, K., & Sani, M. A. (2025) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-025-01544-2 · Cited by 46
Difference in MSA Phenotype Distribution between Populations: Genetics or Environment?
Ozawa, T., Révész, T., Paviour, D. C., Lees, A. J., Quinn, N. P., Tada, M., Kakita, A., Onodera, O., Wakabayashi, K., Takahashi, H., et al. (2012) · Journal of Parkinson s Disease · doi:10.3233/jpd-2012-11056 · Cited by 45
Metadata
- Authors
- Sidransky, E., Nalls, M. A., Aasly, J. O., Aharon-Peretz, J., Annesi, G., Barbosa, E. R., Bar-Shira, A., Berg, D., Bras, J., Brice, A., Chen, C.-M., Clark, L. N., Condroyer, C., De Marco, E. V., Dürr, A., Eblan, M. J., Fahn, S., Farrer, M. J., Fung, H.-C., Gan-Or, Z., Gasser, T., Gershoni-Baruch, R., Giladi, N., Griffith, A., Gurevich, T., Januario, C., Kropp, P., Lang, A. E., Lee-Chen, G.-J., Lesage, S., Marder, K., Mata, I. F., Mirelman, A., Mitsui, J., Mizuta, I., Nicoletti, G., Oliveira, C., Ottman, R., Orr-Urtreger, A., Pereira, L. V., Quattrone, A., Rogaeva, E., Rolfs, A., Rosenbaum, H., Rozenberg, R., Samii, A., Samaddar, T., Schulte, C., Sharma, M., Singleton, A., Spitz, M., Tan, E.-K., Tayebi, N., Toda, T., Troiano, A. R., Tsuji, S., Wittstock, M., Wolfsberg, T. G., Wu, Y.-R., Zabetian, C. P., Zhao, Y., & Ziegler, S. G.
- Affiliations
- National Institutes of Health (US)
- National Human Genome Research Institute (US)
- Corresponding author
- Sidransky, E.
- ORCID
- Sidransky, E.
- Nalls, M.A.
- Aasly, J.O.
- Annesi, G.
- Barbosa, E.R.
- Berg, D.
- Brice, A.
- Chen, C.-M.
- Clark, L.N.
- Condroyer, C.
- Dürr, A.
- Farrer, M.J.
- Fung, H.-C.
- Gasser, T.
- Giladi, N.
- Gurevich, T.
- Kropp, P.
- Lang, A.E.
- Lesage, S.
- Marder, K.
- Mata, I.F.
- Mirelman, A.
- Mitsui, J.
- Mizuta, I.
- Nicoletti, G.
- Oliveira, C.
- Ottman, R.
- Pereira, L.V.
- Quattrone, A.
- Rogaeva, E.
- Rosenbaum, H.
- Rozenberg, R.
- Schulte, C.
- Sharma, M.
- Singleton, A.
- Spitz, M.
- Tan, E.-K.
- Tayebi, N.
- Toda, T.
- Tsuji, S.
- Wittstock, M.
- Wolfsberg, T.G.
- Wu, Y.-R.
- Zabetian, C.P.
- Zhao, Y.
- Ziegler, S.G.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2009-10-22
- Volume
- 361
- Issue
- 17
- Pages
- 1651-1661
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC2856322
- OpenAlex
- W2170281382
- Cited by
- 2,135
- References
- 43
- Citations by year
- 2026: 128 · 2025: 147 · 2024: 156 · 2023: 156 · 2022: 149 · 2021: 155 · 2020: 174 · 2019: 136 · 2018: 135 · 2017: 115 · 2016: 118 · 2015: 118 · 2014: 95 · 2013: 103 · 2012: 84
- FWCI
- 54.96
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Scientific Electronic Library Online (São Paulo Research Foundation, Latin American and Caribbean Center on Health Sciences Information, Conselho Nacional de Desenvolvimento Científico e Tecnológico) (publishedVersion)
- PubMed Central (acceptedVersion)
- National University of Singapore (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- University of Washington
- National Institutes of Health (Z99 HG999999)
- National Institute on Aging (Z01AG000957)
- National Human Genome Research Institute (ZIAHG200336)
- National Institute of Neurological Disorders and Stroke (R56NS036630, R21NS050487, NS 40256, NS050487, R01NS036630, R01NS060113, NS060113)
- National Center for Research Resources (UL1RR024156)
- Topics
- Health Sciences › Medicine › Genetics (clinical) › Lysosomal Storage Disorders Research
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Glycogen Storage Diseases and Myoclonus
- Keywords
- Parkinson's disease, glucocerebrosidase, GBA mutations, Ashkenazi Jews, Gaucher disease, mutation frequency, genotype-phenotype correlation, atypical presentation, familial Parkinson's disease
- MeSH terms
- Aged, Genotype, Glucosylceramidase, Humans, Jews, Middle Aged, Mutation, Parkinson Disease, Multivariate Analysis, Logistic Models, Odds Ratio, Case-Control Studies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.